Monday, March 19, 2018

UNITY Biotechnology Finds $55M

San Francisco-based UNITY Biotechnology, a biotechnology firm developing treatments aimed at slowing, halting, or reversing diseases of aging, has raised $55M in a Series C funding round, the company announced this morning. The funding came from new investors EcoR1 Capital Fund, 6 Dimensions Capital and Altitude Life Science Ventures, plus current investors Fidelity Management & Research Company, Baillie Gifford, Partner Fund Management, Pivotal Alpha Limited, Invus Opportunities, ARCH Venture Partners, Venrock, Founders Fund and the Longevity Fund. The company said the funds will go towards advancing its drug candidates into human clinical trials. More information »